Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance, pharmacokinetics, and metabolism study of oral [14C]-RO4602522 in healthy male volunteers
NL-OMON36882Active, not recruiting
- Sponsor
- Roche
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sembragiline in Alzheimer's disease (AD), sponsored by Roche. Primary endpoints: Routes and rates of elimination of [14C]-RO4602522 and Pharmacokinetics of total drug-related material, RO4602522, and metabolites. Started May 2012; status: active, not recruiting.
02
Drugs
sembragiline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON36882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36882.